CSTL has established a forum for discussions about scientific, technical, ethical, legal, regulatory, security, and other policy issues associated with synthetic biology. The forum will stimulate dialogue about issues of mutual interest to its membership by serving as a venue in which to discuss scientific advances in, challenges and opportunities for, and public policy concerns about synthetic biology. The specific agendas for forum meetings will be determined by the forum membership. It is expected, however, that the forum will begin its consideration of synthetic biology by addressing the near, mid- and far- term technical advances that have potential security and safety aspects and identifying possible strategies to address these aspects during both the development and post-development phases of the emerging technologies. The forum will meet three times in a period of one year with options for two additional years. It may commission papers to inform its discussions and suggest topics for studies, workshops, or other public meetings to be held in conjunction with forum meetings.
This website contains unedited verbatim presentations made by meeting participants and is not an official report of the National Academies. Opinions and statements included in this material are solely those of the individual authors. They have not been verified as accurate, nor do they necessarily represent the views of other participants, the committee, or the National Academies.
September 18-19, 2014
*Sarah R. Carter, "Synthetic Biology and the U.S. Biotechnology Regulatory System: Challenges and Options"
*Thomas M. Connelly, "Synthetic Biology and Advanced Manufacturing - A Chemical Industry Perspective"
*Floyd Romesberg, "Artificial DNA in Living Cells"
*Frank F. Weichold, "FDA Oversight of Synthetic Biology"
March 13, 2014
2nd Meeting: Understanding Risk Frameworks for Emerging Technologies
Palo Alto, CA
*Lynne P. Cooper, "Pre-Quantitative Risk: The Social Construction of Risk in Project Teams"
"Adam Finkel, "Channeling Synthetic Biology Through 'Solution-Focused Risk Assessment'"
*Stephen Hilgartner, "The Politics of Risk"
*Sheila Jasanoff, "International Approaches to Risk (Understanding Risk Frameworks for Emerging Technologies)"
*Jennifer Kuzma, "Beyond Old Debates: New Systems Risk Analysis (NESRA) in an Action Oriented Approach"
*Andrew D. Maynard, "Innovative Approaches to Emergent Risks"
*Jonathan Wiener, "Learning from Research about Risk Regulation"
October 20-21, 2013
*Linda Chrisey, "Office of Naval Research Synthetic Biology"
*Denver Dale, "Specialized Capital Formation and Deployment to Support Synthetic Biology"
*Philip Dormitzer, "Synthetic Vaccinology at Novartis"
*Antony Evans, "Glowing Plant"
*Theresa Good, "NSF Investments in Synthetic Biology"
*Alicia Jackson, "Engineering Biology"
*Megan Palmer, "Enabling Next Generation Synthetic Biology Leadership"
*Alan Pearson, The Role of USDA-APHIS in the Regulation of Biotechnology in the United States"
*Pablo Rabinowicz, "DOE Office of Biological and Environmental Research (BER) Genomic Science Program: Biosystems Design"
*Marc Salit, "National Institute of Standards and Technology"
*Mark Segal, "EPA Oversight of Synthetic Biology"
*William So, "Synthetic Biology and National Security"
August 16, 2013
The Evolving Nature of Synthetic Biology: A Panel Discussion on Key Science, Policy, and Societal Challenges Facing the International Community
*Drew Endy, "What and Why Is Synthetic Biology"
*Richard Johnson, "Synthetic Biology: Ten Policy Reasons It Matters to U.S. Foreign Policy"
*Eleonore Pauwels, "Lost in Translation: Sharing Knowledge on the Technological Frontier"
August 1, 2013
This meeting was closed in its entirety.
July 15-16, 2013
Ownership and Sharing: Setting the Patent Framework for Innovation in Synthetic Biology, A Workshop
*Robert Wells, Synthetic Biology and the Bioeconomy
*Rob Carlson, The Bioeconomy, IP, and Synthetic Biology
*Rochelle C. Dreyfuss, The Patent Landscape: Recent Decisions from the U.S. Supreme Court
*Linda Kahl, How Synthetic Biology Challenges Current Patenting/Ownership Frameworks
*Joanne Kamens, Addgene: A Unique Non-Profit Biotech
*Drew Endy, From Genetic Engineering to Synthetic Biology
*Lionel Clarke, Synthetic Biology Ownership and Innovation: Industry and Other Perspectives
*Stephen Laderman, Case Study: Agilent Technologies - Freedom to Operate
Anne-Marie Mazza, Ph.D.
Director, Committee on Science, Technology, and Law
Steven Kendall, Ph.D.
Program Officer, Committee on Science, Technology, and Law
Program Assistant, Committee on Science, Technology, and Law